These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 19544162)

  • 1. Resolution of corticosteroid-induced diabetes in allergic bronchopulmonary aspergillosis with omalizumab therapy: a novel approach.
    Randhawa I; Chin T; Nussbaum E
    J Asthma; 2009 Jun; 46(5):445-7. PubMed ID: 19544162
    [No Abstract]   [Full Text] [Related]  

  • 2. Omalizumab for treatment of ABPA exacerbations in CF patients.
    Lebecque P; Leonard A; Pilette C
    Pediatr Pulmonol; 2009 May; 44(5):516. PubMed ID: 19382216
    [No Abstract]   [Full Text] [Related]  

  • 3. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis.
    Zirbes JM; Milla CE
    Pediatr Pulmonol; 2008 Jun; 43(6):607-10. PubMed ID: 18433040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence.
    Tanou K; Zintzaras E; Kaditis AG
    Pediatr Pulmonol; 2014 May; 49(5):503-7. PubMed ID: 24167019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omalizumab in the management of steroid dependent allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis.
    Wong R; Wong M; Robinson PD; Fitzgerald DA
    Paediatr Respir Rev; 2013 Mar; 14(1):22-4. PubMed ID: 23287795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab: a new treatment option for allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.
    Lehmann S; Pfannenstiel C; Friedrichs F; Kröger K; Wagner N; Tenbrock K
    Ther Adv Respir Dis; 2014 Oct; 8(5):141-9. PubMed ID: 25150265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab).
    Kanu A; Patel K
    Pediatr Pulmonol; 2008 Dec; 43(12):1249-51. PubMed ID: 19009619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.
    Jat KR; Walia DK; Khairwa A
    Cochrane Database Syst Rev; 2013 Sep; (9):CD010288. PubMed ID: 24043500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis.
    Brinkmann F; Schwerk N; Hansen G; Ballmann M
    Allergy; 2010 Jan; 65(1):134-5. PubMed ID: 19804448
    [No Abstract]   [Full Text] [Related]  

  • 10. Omalizumab treatment for allergic bronchopulmonary aspergillosis in young patients with cystic fibrosis.
    Perisson C; Destruys L; Grenet D; Bassinet L; Derelle J; Sermet-Gaudelus I; Thumerelle C; Prevotat A; Rosner V; Clement A; Corvol H
    Respir Med; 2017 Dec; 133():12-15. PubMed ID: 29173443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment with omalizumab of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis: Case reports and literature review.
    Parisi GF; Portale A; Papale M; Tardino L; Rotolo N; Licari A; Leonardi S
    J Allergy Clin Immunol Pract; 2019; 7(5):1636-1638. PubMed ID: 30772479
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of ABPA: a place for voriconazole and omalizumab?].
    Mulliez P
    Rev Mal Respir; 2010 Sep; 27(7):670-2. PubMed ID: 20863965
    [No Abstract]   [Full Text] [Related]  

  • 13. [Allergic bronchopulmonary aspergillosis: new therapeutic options].
    Germaud P; Pipet A
    Rev Mal Respir; 2010 Sep; 27(7):784-5. PubMed ID: 20863983
    [No Abstract]   [Full Text] [Related]  

  • 14. Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients.
    Nové-Josserand R; Grard S; Auzou L; Reix P; Murris-Espin M; Brémont F; Mammar B; Mely L; Hubert D; Durieu I; Burgel PR
    Pediatr Pulmonol; 2017 Feb; 52(2):190-197. PubMed ID: 27717223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cystic fibrosis: current therapy. Allergic bronchopulmonary aspergillosis (ABPA)].
    Aebischer CC; Schöni MH
    Schweiz Med Wochenschr Suppl; 2000; 122():53S-54S. PubMed ID: 12536477
    [No Abstract]   [Full Text] [Related]  

  • 16. A case of allergic bronchopulmonary aspergillosis treated with omalizumab.
    Sastre I; Blanco J; Mata H; García F
    J Investig Allergol Clin Immunol; 2012; 22(2):145-7. PubMed ID: 22533243
    [No Abstract]   [Full Text] [Related]  

  • 17. [Respiratory deterioration and allergic bronchopulmonary aspergillosis in cystic fibrosis].
    Salcedo Posadas A
    Enferm Infecc Microbiol Clin; 2000; 18(6):301-3. PubMed ID: 11075497
    [No Abstract]   [Full Text] [Related]  

  • 18. [Role of omalizumab in the management of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis].
    Delgado Pecellín I; Quintana Gallego E; Pedregal Solano C; Calero Acuña C
    Med Clin (Barc); 2015 Feb; 144(4):190-1. PubMed ID: 25015245
    [No Abstract]   [Full Text] [Related]  

  • 19. Pulse intravenous methylprednisolone for resistant allergic bronchopulmonary aspergillosis in cystic fibrosis.
    Thomson JM; Wesley A; Byrnes CA; Nixon GM
    Pediatr Pulmonol; 2006 Feb; 41(2):164-70. PubMed ID: 16317722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations:  II. Therapies for allergic bronchopulmonary aspergillosis.
    Epps QJ; Epps KL; Zobell JT; Young DC
    Pediatr Pulmonol; 2020 Dec; 55(12):3541-3572. PubMed ID: 32946194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.